Correspondence 0001193125-23-265802 from Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687) (RNAC)

Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)
Date: Oct. 30, 2023 · CIK: 0001453687 · Accession: 0001193125-23-265802

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-275171

Date

October 30, 2023

Author

Form

CORRESP

Company

Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)

Letter

Re: Selecta Biosciences, Inc.

October 30, 2023

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Tamika Sheppard

Registration Statement Filed on Form S-3 (the “Registration Statement”)

File No. 333-275171

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Selecta Biosciences, Inc. (the “Company”) hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on November 1, 2023, or as soon as practicable thereafter.

Please contact Sarah C. Griffiths of Covington & Burling LLP at (617) 603-8815 or sgriffiths@cov.com with any questions you may have regarding this request. In addition, please notify Ms. Griffiths by telephone when this request for acceleration has been granted.

Respectfully,
Selecta Biosciences, Inc.

Show Raw Text

CORRESP
1
filename1.htm

CORRESP

 October 30, 2023

Via EDGAR

 U.S. Securities and Exchange Commission

Division of Corporation Finance

 100 F Street, N.E.

Washington, D.C. 20549

 Attn: Tamika Sheppard

Re:
 Selecta Biosciences, Inc.

Registration Statement Filed on Form S-3 (the “Registration Statement”)

File No. 333-275171

Ladies and Gentlemen:

 Pursuant to Rule 461
under the Securities Act of 1933, as amended, Selecta Biosciences, Inc. (the “Company”) hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on
November 1, 2023, or as soon as practicable thereafter.

 Please contact Sarah C. Griffiths of Covington & Burling LLP at
(617) 603-8815 or sgriffiths@cov.com with any questions you may have regarding this request. In addition, please notify Ms. Griffiths by telephone when this request for acceleration has been granted.

Respectfully,

Selecta Biosciences, Inc.

By:

/s/ Carsten Brunn, Ph.D.

Name:

Carsten Brunn, Ph.D.

Title:

President and Chief Executive Officer

 cc: Sarah C. Griffiths, Covington & Burling LLP

SecProbe.io